“The industry is back, and we’re uniquely positioned to provide end-to-end services, including clinical trials. That’s what we mean by CDMO plus CRO – it’s a complete 360-degree set of operations,” says Dr. Anil Kane, Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific.

Dr. Kane leads Thermo Fisher’s technical and scientific initiatives, bringing extensive experience in pharmaceutical development and manufacturing. His expertise spans multiple modalities, from small molecules to advanced therapies, positioning him at the forefront of innovative drug development solutions.

Speaking to the PharmaSource podcast at CPHI Milan, Dr. Kane explained Thermo Fisher’s latest initiative, Accelerator™ Drug Development, which combines their Contract Development and Manufacturing Organisation (CDMO) capabilities with Contract Research Organisation (CRO) services from their PPD acquisition. This integrated approach aims to streamline the complex journey from pre-clinical development to commercialisation, offering a truly connected and customisable suite of services.

The 2021 acquisition of PPD marked a pivotal moment in Thermo Fisher’s evolution, enabling the creation of a comprehensive service offering that spans the entire drug development spectrum. This integration brings together:

• Drug substance development


• Drug product development


• Clinical trial packaging and labeling services


• Full clinical trial management


• Specialised GMP laboratory testing


• Regulatory documentation support

“This combination of services brings efficiency, reducing cost and time for our partners to run drug development from very early stage, through clinical phases, to approval and bringing medicines to patients faster,” explains Kane. “We help our clients even put documentations together for IND, NDA, and other regulatory submissions.”

Read the full interview on PharmaSource